logo-loader
HealthCannabis
MGC Pharmaceuticals Ltd

MGC Pharmaceuticals commencing production of CannEpil for epilepsy

Pre-registered patients for the drug is set to generate over $1 million in sales.

medicinal cannabis indoor crop
Once the first batch is produced, it will be inspected by the GMP regulatory body

MGC Pharmaceuticals Ltd (ASX:MXC) is today commencing production of its first batch of CannEpil at its European medicinal cannabis facility.

CannEpil is MXC’s first pharmaceutical-grade medical cannabis product targeting people with drug-resistant epilepsy.

Good Manufacturing Practice certification

Production was able to start at the manufacturing facility thanks to the receipt of its interim Good Manufacturing Practice (GMP) certification.

Once the first batch is produced, it will be inspected by the GMP regulatory body.

This is the final regulatory process before full GMP certification can be granted to MGC’s European manufacturing facility.

Expected to generate over $1 million in annual sales in the Australian market

Once the distribution of CannEpil commences, it is expected to generate more than $1 million in annual sales in the Australian market in its first year.

This estimate is based on the near-100 patients already registered but the Australian market opportunity for MGC is much larger.

MGC estimates 72,000 people are diagnosed with drug-resistant epilepsy in Australia.

MGC’s co-founder and CEO Roby Zomer said: “The production of our first CannEpil batch is a milestone, and leaves us well positioned to achieve certification and commence full-scale commercial production in the next few months.”

Quick facts: MGC Pharmaceuticals Ltd

Price: $0.04

Market: ASX
Market Cap: $53.3 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Northern Minerals reveals talks with US government agencies,...

Northern Minerals Ltd (ASX:NTU) CEO George Bauk tells Proactive he recently met US government agencies, who he says wanted to get a better sense of the Australian company's progress with its dysprosium production, and its strategy going forward. Bauk is currently in New York meeting with...

3 days ago

2 min read